List of Research Projects Utilizing the Repository
Specimens and data provided by contributors are stored in the repository and will be applied to research following reviews from the utilization subcommittee. Details from each study can be found in the list below.
Regarding representative research institutions and principal investigators, cases in which applicants requested not to disclose information (such as companies or academia) have data indicated as “non-disclosed.”
Please contact us here if, after reviewing the research details in the research project list, you do not wish for your or your family’s specimens or data to be utilized.
Research Outcomes from Repository Utilization
Publications
〈2025〉
Predictors of in-hospital death among patients with COVID-19 aged < 65 who required invasive mechanical ventilation in JapanNew
Using multicenter COVID Registry data collected through June 2021, this study identified predictors of in-hospital death among COVID-19 patients under 65 years of age who received invasive mechanical ventilation. Among the 728 patients included in the analysis (median age, 55 years [interquartile range, 49.5-60]; 84.8% male), 10% (73/728) died during hospitalization. Among those discharged alive, 46.6% (305/655) required supplemental oxygen at the time of discharge. Logistic regression analysis adjusted for age and sex identified comorbidities and other factors associated with in-hospital mortality.
Taniguchi Y, Hosozawa M, Kimura H, Kitajima K, Ohmagari N, Iso H. Predictors of in-hospital death among patients with COVID-19 aged < 65 who required invasive mechanical ventilation in Japan. Respir Med. 2025 Aug 5;247:108289.
https://doi.org/10.1016/j.rmed.2025.108289
Discovery of the clinical candidate S-892216: A second-generation of SARS-CoV-2 3CL protease inhibitor for treating COVID-19New
Unoh Y, Hirai K, Uehara S, Kawashima S, Nobori H, Sato J, Shibayama H, Hori A, Nakahara K, Kurahashi K, Takamatsu M, Yamamoto S, Zhang Q, Tanimura M, Dodo R, Maruyama Y, Sawa H, Watari R, Miyano T, Kato T, Sato T, Tachibana Y. Discovery of the clinical candidate S-892216: A second-generation of SARS-CoV-2 3CL protease inhibitor for treating COVID-19. J Med Chem. 2025 Jul 5.
https://doi.org/10.1021/acs.jmedchem.5c00754
SARS-CoV-2 BA.2.86 is susceptible to the neutralizing antibody MO11 targeting subdomain 1 despite the E554K mutation near the epitopeNew
Hasegawa N, Nishimura M, Takamiya R, Ishimaru H, Mori Y. SARS-CoV-2 BA.2.86 is susceptible to the neutralizing antibody MO11 targeting subdomain 1 despite the E554K mutation near the epitope. J Virol. 2025 Feb 25;99(2):e0138924.
https://doi.org/10.1128/jvi.01389-24
〈2024〉
Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2
Kinoshita H, Yamamoto T, Kuroda Y, Inoue Y, Miyazaki K, Ohmagari N, Tokita D, Nguyen P, Yamada S, Harada S, Kanno T, Takahashi K, Saito M, Shirato K, Takayama I, Watanabe S, Saito T, Ebihara H, Suzuki T, Maeda K, Fukushi S. Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2. Scientific Reports. 2024 Oct 22;14(24858).
https://doi.org/10.1038/s41598-024-75038-4
Other
〈2025〉
In Vitro Evaluation of Therapeutic Compounds Against Viruses with Pandemic PotentialNEW
As part of a contracted study, three virus strains amplified in this study were inoculated into cells provided by the client to generate virus stocks. These stocks were then used for in vitro evaluation of compounds supplied by the client. The commercial use described above had been declared in advance at the time of the REBIND resource utilization application.
Neutralizing Antibody Titer Measurement for Various SARS-CoV-2 Variants to Support Domestic Vaccine DevelopmentNew
Our company has been providing neutralizing antibody titer measurement services on a commercial basis since March 2025 under contracts with external organizations.
Shuji Kanayama, BML, Inc.
Interim Report (5) on the Health Status Survey Following Booster Vaccination with Daiichi Sankyo's Monovalent Omicron XBB.1.5 COVID-19 Vaccine
Research Project on Emerging and Re-emerging Infectious Diseases and Immunization Policy: Cohort Study Including Domestic COVID-19 Vaccines in Preparation for the Transition from Temporary Special Vaccination Programs to Routine Immunization
Suminobu Ito, Juntendo University, 106th Meeting of the Adverse Events Review Committee of the Health Sciences Council Vaccination and Vaccine Subcommittee and the 1st FY2025 Meeting of the Pharmaceutical Affairs Council Committee on Drug Safety Measures Investigation (Joint Meeting) (See the Subcommittee page), April 14, 2025